ASX200 climbs half a per cent – comfortably eclipsing futures’ forecasts

The ASX200 was having its best day in a fortnight as it hit 7829 in mid-morning trade, coming off record highs of 7860 earlier in the month. All sectors are in the green mid-session.

In this bulletin, we’ll look at news from Pilbara Minerals, Argenica Therapeutics, and LTR Pharma.

In company news,

Pilbara Minerals (ASX;PLS) has inked a downstream partnership agreement with Chinese company Ganfeng – a leader and major supplier of lithium chemicals globally – to complete a joint feasibility study on a 32-thousand tonnes per annum downstream lithium conversion plant in Australia.

The feasibility study is expected to be complete by March 2025.

PLS has been trading at $3.87.

Argenica Therapeutics (ASX:AGN) is up more than 14 per cent after winning rare pediatric disease designation (RPDD) for its flagship drug ARG-007 – a treatment Argenica is hoping to commercialise as a drug to improve outcomes in infants with brain tissue complications following brain injury.

AGN has been trading at 65 cents.

And LTR Pharma (ASX:LTP) has made further progress with SPONTAN®, its ground-breaking nasal spray treatment for erectile dysfunction (ED); and has now completed the recruitment and dosing for its pivotal clinical study. 

Study results are anticipated by mid-year, and LTR Pharma is hoping SPONTAN could reshape the landscape of ED treatment.

LTP has been trading at 31.5 cents.